Indaptus Therapeutics Reports Third Quarter 2026 Financial Results

Indaptus Therapeutics reported a net loss of approximately $1.0 million for the third quarter of 2026, compared to $3.0 million in the same period of 2025. Research and development expenses fell by 82% to approximately $0.3 million, primarily due to lower clinical costs for the Decoy20 Phase 1 study and reduced payroll expenses. General and administrative expenses also decreased by 24% to approximately $0.9 million. As of September 30, 2026, the company held approximately $30.6 million in cash, cash equivalents, and short-term investments. Additionally, the company noted a private placement completed in October 2026, which generated aggregate gross proceeds of approximately $24.0 million.